BioNTech Shares Fall Roughly 7% After BNT113 Trial Miss
BioNTech shares closed down roughly 7% Tuesday after its investigational mRNA cancer immunotherapy BNT113 failed to show a statistically significant progression-free survival benefit in a late-stage trial. An analyst linked the result to broader mRNA cancer-vaccine struggles.
BioNTech shares (BNTX) closed down roughly 7% on Tuesday after the company reported that its investigational mRNA cancer immunotherapy BNT113 failed to show a statistically significant progression-free survival (PFS) benefit in a key late-stage trial, a result an analyst said reflects a broader pat…